Imatinib Mesylate and Gray Hair

8 August 2002

journal article
letter
Published by Massachusetts Medical Society in New England Journal of Medicine

Vol. 347 (6) , 446
https://doi.org/10.1056/nejm200208083470614

Abstract

The impressive effects of the tyrosine kinase inhibitor STI571 (imatinib mesylate) in chronic myeloid leukemia were confirmed in the large trial by Kantarjian et al. (Feb. 28 issue).¹ We would like to report a new side effect of the drug.

Keywords

IMATINIB MESYLATE
IMPRESSIVE EFFECTS
KINASE INHIBITOR
SIDE EFFECT
POPUP CONTENT
DATA BEHAVIOR
TYROSINE KINASE
GRAY HAIR

This publication has 2 references indexed in Scilit:

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
Blood, 2002
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
New England Journal of Medicine, 2002